Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 294.00
Bid: 292.00
Ask: 298.00
Change: -3.00 (-1.01%)
Spread: 6.00 (2.055%)
Open: 294.00
High: 294.00
Low: 294.00
Prev. Close: 298.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

Thu, 04th Jun 2020 13:19

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Thursday and not separately reported by Alliance News:

----------

Open Orphan PLC - pharmaceutical services - Launches antibody testing service, hVIVO Covid Clear Test, following the successful completion of installation, testing and training. Test will be offered to large employer groups and channel partners including GP networks, nursing services, health clinics and private hospitals. Samples will be tested in the company's London laboratory with results returned within 48 hours.

----------

PureTech Health PLC - biotherapeutics - Founded entity Follica reports positive feedback from an end of Phase 2 meeting with the US Food & Drug Administration for its lead programme to treat male androgenetic alopecia. Follica plans to advance the programme into phase 3 development in 2020 following the successful safety and efficacy optimisation study announced in December 2019.

----------

Hutchison China Meditech Ltd - biopharmaceutical - Independent Data Monitoring Committee of the Frutiga study of fruquintinib has completed a planned interim data review and has recommended continuation of the trial. Frutiga is a phase III trial in China of fruquintinib in combination with paclitaxel in the treatment of patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have progressed after first-line standard chemotherapy.

----------

Oncimmune Holdings PLC - immunodiagnostics - Revenue to be in line with market expectations for year to May 31, with further strong growth expected in financial 2021. Cash at year-end expected to be GBP4.2 million and net debt of GBP3.1 million. Next 18 months expected to create substantial revenues within the EarlyCDT product business. Pipeline of contracts within the ImmunoInsights services business building. Geoffrey Hamilton-Fairley, non-executive vice chair; Julian Hirst, independent non-executive director; and Carsten Schroeder, independent non-executive director, have stepped down with immediate effect following board restructuring.

----------

Loungers PLC - bars and restaurants - Opened 17 sites for take-out and will open a further 10 sites on the same basis over the next week. Choses not to go down the delivery route. Looking to trial order-at-table technology and considering menu size. Plans to trial going cashless after re-opening. Anticipating some of sites being allowed to open in July. Expects to trade profitably with social distancing rules in place.

----------

Personal Group Holdings PLC - employee benefits - Too early to accurately assess eventual impact of Covid-19 on the company. Made an encouraging start to 2020. Switched salesforce to telesales to retain and recapture insurance policyholders. Introduced new company-wide pandemic insurance product for clients. Paying out on Covid-19 claims and supporting bereaved families and hospitalised policyholders. Negotiating significant potential new Let's Connect and Insurance clients.

----------

XP Power Ltd - power control components - All manufacturing and logistics facilities currently operational. Operational performance continuing to improve following the extended shutdown of Chinese manufacturing facility in February, and the associated supply chain challenges. Local supply chains in China and Vietnam are working at pre-Covid-19 capacity levels. Trading during April and May encouraging. Order intake in April and May continues to be strong. Sees exceptional levels of demand from its Healthcare customers. Expects this demand to normalise in second half of 2020. Revenue for five months to May-end up 7% year-on-year at GBP86.3 million. Year-to-date orders up 52% at GBP128.0 million. Net debt GBP38.0 million at May 31. Good near-term visibility due to strong order book.

----------

Randall & Quilter Investment Holdings Ltd - insurance - Completes loss portfolio transfer from Houston International Insurance Group. Agreement provides reinsurance protection and limited adverse development cover for circa USD95 million of net reserves of three companies in Houston International - Houston Specialty Insurance Co, Imperium Insurance Co and Great Midwest Insurance Co. The reserves relate to the companies' 2017 and prior policy years for certain portfolios.

----------

Clear Leisure PLC - investments - Shareholder Eufingest SA agreed to extend repayment of loans worth EUR3.9 million and GBP30,000 to September 30 or such earlier date as may be agreed with Clear Leisure.

----------

Kazera Global PLC - investment - Acquires a controlling interest in a near-term producing diamond mine and in a heavy mineral sands opportunity in South Africa. To buy a 90% stake in Deep Blue Minerals (Pty) Ltd and a stake in Whale Head Minerals (Pty) Ltd. Acquisition cost of the stake in Deep Blue Minerals is GBP600,000 funded via issue of 120 million ordinary shares at 0.5 pence each. To buy a stake in Whale Head Minerals representing 90% of its issued capital. To assume USD500,000 of liabilities from the vendor of the shares in Whale Head Minerals.

----------

Cluff Natural Resources PLC - natural resources investments - Fully committed to drilling Pensacola and Selene prospects in UK North Sea. To begin farm-out process on a further two of its licences in the second half of 2020. Applied for multiple licences in the UK 32nd offshore licensing round, with results expected this summer. In a strong financial position with cash of GBP13.2 million as at March 31. Will review opportunities, including the potential to acquire cash generative production portfolios. To seek shareholder approval to rename itself Deltic Energy PLC.

----------

Pure Gold Mining Inc - mining - Drilling restarts at PureGold Red Lake mine in Red Lake, Canada. Over 30,000 meters of diamond drilling, including both underground and surface drilling, is planned to optimize the near term mine plan, expedite the growth of our mineral resources and aggressively expand new high-grade discoveries. Over 30,000 meters of diamond drilling, including both underground and surface drilling, planned to optimize the near term mine plan, expedite the growth of our mineral resources and aggressively expand new high-grade discoveries.

----------

Hummingbird Resources PLC - gold mining - Inks earn-in agreement with ARX Resources Ltd for the company's Dugbe Gold project located in Liberia. Pact requires ARX completing a definitive feasibility study, carry out a significant exploration programme and cover all project costs over the two year earn-in period. Earn-in entitles ARX to earn up to a 49% interest in the project, and includes the payment by ARX to Hummingbird of a non-refundable deposit of USD2 million. Hummingbird secures the right to acquire an exploration licence in Liberia, which is surrounded on all sides by the company's existing mineral development agreement.

----------

Blackbird PLC - cloud video editing platform - Sports and live event production specialist Whisper has chosen Blackbird to drive major video production efficiencies for its clients, including Formula One. Whisper production team will use Blackbird's toolset to remotely edit and enrich documentaries, interviews and behind-the-scenes long form content.

----------

Codemasters Group Holdings PLC - video games - To release Project CARS 3 game in late summer 2020 for PlayStation 4 and the Xbox One family of devices.

----------

Elecosoft PLC - architectural and engineering software - Revenue for four months to April 30 down 3% year-on-year. Recurring maintenance, support and subscription revenue 6% higher. Pretax profit up 25% year-on-year. Net cash of GBP3.1 million at April 30.

----------

CyanConnode Holdings PLC - machine-to-machine communication - Substantial contract from Indian utility, Jaipur Vidyut Vitran Nigam Ltd, relating to two projects, which had been delayed, has now received the necessary approvals to resume the implementation. Further steps taken to reduce cost base amid virus disruption. Thai contract continues to meet project deliverables and payments were received from the customer at the end of March and May.

----------

Van Elle Holdings PLC - ground engineering - Appoints former Galliford Try PLC's chief financial officer Frank Nelson as a non-executive director and chair designate, replacing outgoing Adrian Barden. April trading consistent with revised assumptions, with revenue at 20% of pre Covid-19 forecast levels. Revenue for year to April 30 down 4% year-on-year at GBP85 million. To report an underlying pre-tax loss for financial 2020 due to a significant adverse impact from virus outbreak. Not appropriate to reinstate guidance for financial 2021. Customer activity levels beginning to increase. Order book at April 30 in line with the half year position at GBP31.7 million, although enquiry levels have reduced by circa 20% compared to previous levels. Cash of GBP12 million at May 31. In talks for additional debt facilities.

----------

Dillistone Group PLC - recruitment technology - Gets GBP1.5 million under UK government's coronavirus loan scheme. To use loan for working capital purposes, including development of existing and new products. Range of likely outcomes for 2020 has significantly improved. Too early to quantify the impact of the pandemic over 2020, however, the most likely outcome for first half will be a small loss.

----------

By Tapan Panchal; tapanpanchal@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
12 Sep 2023 11:26

Hutchmed reports progress on two oncology fronts

(Sharecast News) - Hutchmed China reported significant strides in oncology research on Tuesday, completing patient enrollment for a bridging study of tazemetostat, and announcing pivotal results for the phase 3b clinical trial of savolitinib.

Read more
12 Sep 2023 10:26

IN BRIEF: Hutchmed China finalises patient enrolment for Tazemetostat

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Completes patient enrolment for bridging phase two study in China to evaluate the efficacy of cancer drug Tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma. Tazemetostat is approved by the US Food & Drug Administration for the treatment of advanced epithelioid sarcoma and R/R FL.

Read more
29 Aug 2023 13:38

Hutchmed tumour therapy candidate gets breakthrough designation

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced on Tuesday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to its investigational drug savolitinib.

Read more
29 Aug 2023 09:30

IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Wins 'breakthrough therapy designation' in China for its gastric cancer treatment, savolitinib. The BTD is granted by the National Medical Products Administration. It is for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies. Hutchmed notes that MET-driven gastric cancer has a poor prognosis, and China grants a BTD to new drugs that treat life-threatening diseases for which there are no effective treatment options.

Read more
21 Aug 2023 08:46

Hutchmed China hails trial on sovleplenib meeting primary endpoint

(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint.

Read more
21 Aug 2023 08:24

Hutchmed meets all endpoints in platelet disorder treatment trial

(Sharecast News) - Hutchmed China reported a breakthrough from its recent phase three trial in sovleplenib on Monday, reporting that it met its primary endpoint and all secondary endpoints for treating adult patients with primary immune thrombocytopenia - a platelet disorder - (ITP) in China.

Read more
31 Jul 2023 12:47

Hutchmed swings to profit after "sharpening goals and priorities"

(Alliance News) - Hutchmed (China) Ltd on Monday reported sharp first-half revenue growth, as a strategy change to boost its fortunes outside of China saw early fruit.

Read more
24 Jul 2023 15:46

UK earnings, trading statements calendar - next 7 days

Tuesday 25 July 
City of London Investment Group PLCTrading Statement
Compass Group PLCTrading Statement
Croda International PLCHalf Year Results
Games Workshop Group PLCFull Year Results
Greencore Group PLCTrading Statement
Hummingbird Resources PLCTrading Statement
MITIE Group PLCTrading Statement
Paragon Banking Group PLCTrading Statement
Reach PLCHalf Year Results
Smart Metering Systems PLCTrading Statement
Tristel PLCTrading Statement
Tyman PLCHalf Year Results
Unilever PLCHalf Year Results
Unite Group PLCHalf Year Results
Wednesday 26 July 
Aptitude Software Group PLCHalf Year Results
Breedon Group PLCHalf Year Results
Conduit Holdings LtdHalf Year Results
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
FRP Advisory Group PLCFull Year Results
Gresham Technologies PLCHalf Year Results
Lloyds Banking Group PLCHalf Year Results
Marston's PLCTrading Statement
Nichols PLCHalf Year Results
Primary Health Properties PLCHalf Year Results
Rathbones Group PLCHalf Year Results
Revolution Bars Group PLCTrading Statement
Rio Tinto PLCHalf Year Results
Science Group PLCHalf Year Results
Van Elle Holdings PLCFull Year Results
Thursday 27 July 
Allianz Technology Trust PLCHalf Year Results
Antofagasta PLCHalf Year Results
Capital & Regional PLCHalf Year Results
Card Factory PLCTrading Statement
Checkit PLCTrading Statement
Drax Group PLCHalf Year Results
Deliveroo PLCHalf Year Results
Derwent London PLCHalf Year Results
Entain PLCHalf Year Results
Greencoat UK Wind PLCHalf Year Results
Global Connectivity PLCHalf Year Results
Hostelworld Group PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Lancashire Holdings LtdHalf Year Results
Mitchells & Butlers PLCTrading Statement
OSB Group PLCHalf Year Results
Persimmon PLCHalf Year Results
Petrofac LtdHalf Year Results
Redcentric PLCFull Year Results
S&U PLCTrading Statement
Savills PLCHalf Year Results
Secure Trust Bank PLCHalf Year Results
Spirax-Sarco Engineering PLCHalf Year Results
Videndum PLCHalf Year Results
Wheaton Precious Metals CorpHalf Year Results
Friday 28 July 
AIB Group PLCHalf Year Results
GCP Infrastructure Investments LtdTrading Statement
International Consolidated Airlines Group SAHalf Year Results
Intertek Group PLCHalf Year Results
Jardine Matheson Holdings LtdHalf Year Results
NatWest Group PLCHalf Year Results
PayPoint PLCFull Year Results
PayPoint PLCTrading Statement
Standard Chartered PLCHalf Year Results
YouGov PLCTrading Statement
Monday 31 July 
Hutchmed (China) LtdHalf Year Results
Pearson PLCHalf Year Results
Pod Point Group Holdings PLCHalf Year Results
Quartix Technologies PLCHalf Year Results
Spectris PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
20 Jul 2023 14:14

IN BRIEF: Hutchmed progresses fruquintinib designation and testing

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Granted breakthrough therapy designation, by the Center for Drug Evaluation of China's National Medical Products Administration, for oral inhibitor fruquintinib combined with PD-1 antibody sintilimab. BTD is for treatment of patients with previously treated advanced endometrial cancer.

Read more
10 Jul 2023 12:58

Hutchmed launches new phase one study in China

(Sharecast News) - Biopharmaceutical company Hutchmed China announced the launch of a phase one study in China for HMPL-415 on Monday - an investigational selective allosteric inhibitor that targeted Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2).

Read more
10 Jul 2023 08:53

IN BRIEF: Hutchmed starts study for tumour treatment in China

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.

Read more
16 Jun 2023 08:51

Hutchmed, Takeda Fresco-2 study published in The Lancet

(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet.

Read more
16 Jun 2023 08:44

Hutchmed China's colorectal cancer study to be published

(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.

Read more
15 Jun 2023 16:51

IN BRIEF: Hutchmed and Takeda get Europe marketing backing for drug

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.

Read more
26 May 2023 13:13

US FDA gives priority to Hutchmed's colorectal cancer treatment

(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.